The novel renin inhibitor XII demonstrates potent, specific in vitro activity and prolonged in vivo hypotensive effects in a primate model.
Answers are grounded in this paper and cite their sources.
Supports renin inhibitor development in primates; leaves open translation to human hypertension therapy.
A structure-activity analysis of peptides containing backbone C alpha-methyl and N alpha-methyl modifications led to the discovery of potent renin inhibitors with high metabolic stability. In vitro, Boc-Pro-Phe-N alpha-MeHis-Leu psi-[CHOHCH2]Val-Ile-Amp (XII) is a potent inhibitor of human plasma renin with IC50 of 0.26 nM. It is a much weaker inhibitor of other aspartic proteases such as porcine pepsin or bovine cathepsin D (IC50 = 6 microM). It was shown not to be degraded by a rat liver homogenate preparation. In vivo, it inhibited plasma renin activity and lowered blood pressure of furosemide-treated cynomolgus monkeys. At a dose of 5 mg/kg iv, the pronounced hypotensive response persisted for greater than 3 h postinfusion.
No takes yet. Share an insight, caveat, or question.
Thaisrivongs et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: